CNBC interview explores GLP-1 weight loss adoption, clinically backed nutrition, preventative health and the evolving consumer wellness landscape
| Source: Rapid Nutrition Plc
LONDON, June 08, 2026 (GLOBE NEWSWIRE) — Rapid Nutrition PLC (Euronext Growth: ALRPD), a global HealthTech company advancing wellness through evidence-based, personalized nutrition solutions, advises that CEO Simon St Ledger was featured on CNBC discussing GLP-1 weight loss trends, clinically backed nutrition, preventative health and the future of consumer wellness.
CNBC is one of the world’s leading business news networks, reaching a global audience of investors, business leaders and consumers.
The interview explored how the rapid adoption of GLP-1 weight loss medications is reshaping the global conversation around weight management, increasing focus on complementary areas including muscle preservation, nutritional adequacy, behavioural change and long-term health outcomes.
The discussion also highlighted Rapid Nutrition’s participation in the ongoing U.S.–Australia TOPS (The Osteoarthritis Prevention Study), a major clinical study examining structured lifestyle interventions and nutrition in women over 50. Management believes the growing convergence of weight management, healthy ageing, mobility and preventative health represents a significant long-term opportunity across consumer wellness markets.
The TOPS study forms part of the Company’s broader clinically aligned wellness strategy, including its flagship SystemLS platform, which focuses on sustainable weight management, protein-supported nutrition and long-term lifestyle engagement.
The interview also provided insight into Rapid Nutrition’s broader HealthTech strategy, which combines clinical research, digital engagement, artificial intelligence, personalised wellness support and retail distribution into an integrated consumer wellness ecosystem designed to support individuals throughout their health journey.
Commenting during the interview, Simon St Ledger stated:
“The real opportunity is not more information, but helping people act on it in a practical and consistent way.”
Mr St Ledger added:
“The next phase of health is not reactive — it is guided in real time.”
— Simon St Ledger, CEO, Rapid Nutrition PLC
The full CNBC interview is available via the Company’s website and investor relations channels. Shareholders and interested parties are encouraged to visit www.rnplc.com for further updates.
About Rapid Nutrition
Rapid Nutrition PLC is a global HealthTech company advancing wellness through evidence-based, personalized nutrition solutions. By leveraging artificial intelligence, advanced technologies, and clinical research, the company delivers products and programs designed to optimize nutrition, improve health outcomes, and promote sustainable, healthier lifestyles worldwide.
Investor Relations Contact:
ir@rnplc.com
Investor Access (24/7 AI Platform)
+1 (855) 77-ALRPD
Cautionary Statement Regarding Forward-Looking Statements
This announcement contains forward-looking statements, including statements regarding the Company’s strategy, market opportunities, industry trends, product development activities, clinical research initiatives and future business prospects. Forward-looking statements are based on management’s current expectations, assumptions and beliefs and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements.
Forward-looking statements speak only as of the date of this announcement and should not be regarded as a representation that future plans, expectations or objectives will be achieved. Except as required by applicable law or regulation, Rapid Nutrition PLC undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements are provided for illustrative purposes only and are not guarantees of future performance.
Market Abuse Regulation
This announcement has been prepared in accordance with the Company’s disclosure obligations under applicable market abuse and market disclosure regulations. The Company does not consider the information contained in this announcement to constitute inside information at the time of publication.
